CN105848662A - 杀肿瘤和抗微生物组合物和方法 - Google Patents

杀肿瘤和抗微生物组合物和方法 Download PDF

Info

Publication number
CN105848662A
CN105848662A CN201480068072.8A CN201480068072A CN105848662A CN 105848662 A CN105848662 A CN 105848662A CN 201480068072 A CN201480068072 A CN 201480068072A CN 105848662 A CN105848662 A CN 105848662A
Authority
CN
China
Prior art keywords
compositions
cells
cell
pharmaceutical composition
pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480068072.8A
Other languages
English (en)
Chinese (zh)
Inventor
H·G·克林格曼
B·J·西蒙
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunitybio Inc
Original Assignee
NantKwest Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NantKwest Inc filed Critical NantKwest Inc
Priority to CN202510641320.3A priority Critical patent/CN120501764A/zh
Publication of CN105848662A publication Critical patent/CN105848662A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/44—Fungal antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5068—Cell membranes or bacterial membranes enclosing drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A40/00—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production
    • Y02A40/70—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production in livestock or poultry

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Botany (AREA)
  • Developmental Biology & Embryology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CN201480068072.8A 2013-11-01 2014-10-28 杀肿瘤和抗微生物组合物和方法 Pending CN105848662A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202510641320.3A CN120501764A (zh) 2013-11-01 2014-10-28 杀肿瘤和抗微生物组合物和方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361899066P 2013-11-01 2013-11-01
US61/899,066 2013-11-01
PCT/US2014/062695 WO2015066054A1 (en) 2013-11-01 2014-10-28 Tumoricidal and antimicrobial compositions and methods

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202510641320.3A Division CN120501764A (zh) 2013-11-01 2014-10-28 杀肿瘤和抗微生物组合物和方法

Publications (1)

Publication Number Publication Date
CN105848662A true CN105848662A (zh) 2016-08-10

Family

ID=53005034

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201480068072.8A Pending CN105848662A (zh) 2013-11-01 2014-10-28 杀肿瘤和抗微生物组合物和方法
CN202510641320.3A Pending CN120501764A (zh) 2013-11-01 2014-10-28 杀肿瘤和抗微生物组合物和方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202510641320.3A Pending CN120501764A (zh) 2013-11-01 2014-10-28 杀肿瘤和抗微生物组合物和方法

Country Status (9)

Country Link
US (10) US10258649B2 (enExample)
EP (3) EP3701957B1 (enExample)
JP (2) JP6603216B2 (enExample)
KR (5) KR20220147705A (enExample)
CN (2) CN105848662A (enExample)
AU (1) AU2014342477B2 (enExample)
CA (1) CA2927977C (enExample)
ES (1) ES2935906T3 (enExample)
WO (1) WO2015066054A1 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108324735A (zh) * 2017-01-20 2018-07-27 李莉 用于疾病治疗的胞外体制剂及其应用
CN108815186A (zh) * 2018-06-14 2018-11-16 上海鸣大生物科技有限公司 一种治疗hpv持续感染引起疾病的药物及制备方法与应用
CN109804064A (zh) * 2016-09-29 2019-05-24 南克维斯特公司 具有降低的免疫原性的hla i类缺陷的nk-92细胞
CN111670246A (zh) * 2018-01-31 2020-09-15 南克维斯特公司 5%人白蛋白在洗涤和收获培养基中的用途

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105848662A (zh) 2013-11-01 2016-08-10 南克维斯特公司 杀肿瘤和抗微生物组合物和方法
EP4424326A3 (en) * 2015-06-10 2024-11-13 ImmunityBio, Inc. Modified nk-92 cells for treating cancer
CA3007996A1 (en) * 2015-12-09 2017-06-15 Nant Holdings Ip, Llc Compositions and methods for treatment of her2 positive metastatic breast cancer
US11142552B2 (en) * 2016-07-19 2021-10-12 National Institute Of Plant Genome Research Protein against fungal pathogens
US20200163993A1 (en) * 2017-05-09 2020-05-28 Saint Louis University Treatment of cancer and infectious diseases with natural killer (nk) cell-derived exosomes
WO2021028787A1 (en) * 2019-08-12 2021-02-18 Advaccine (Suzhou) Biopharmaceuticals Co. Ltd. Immune composition comprising respiratory syncytial virus (rsv) g polypeptide
WO2025221993A1 (en) 2024-04-18 2025-10-23 Immunitybio, Inc. Compositions and methods for producing il-16

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040018183A1 (en) * 1997-04-30 2004-01-29 Hans Klingemann Modified natural killer cell lines and methods of use
WO2013025598A1 (en) * 2011-08-12 2013-02-21 The Children's Hospital Of Philadelphia Degranulation indicator and methods of use thereof
CN103154731A (zh) * 2010-07-28 2013-06-12 坎瓦克斯生物技术公司 新的超灵敏的基于细胞的传感器及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8034332B2 (en) 1997-04-30 2011-10-11 Conkwest, Inc. Interleukin-secreting natural killer cell lines and methods of use
KR20130008081A (ko) 2004-02-13 2013-01-21 바스프 뷰티 케어 솔루션즈 프랑스 에스에이에스 카스타니아 사티바의 잎 추출물을 포함하는 미용 조성물
JP2008505071A (ja) 2004-07-02 2008-02-21 アヴァリス・アクチエボラーグ 細胞を遺伝学的に活性化する方法、および、該細胞の使用
DK2112162T3 (da) 2004-07-10 2015-02-23 Fox Chase Cancer Ct Genetisk modificerede humane naturlige dræbercellelinjer
CA2605781A1 (en) 2005-05-09 2007-04-12 Glycart Biotechnology Ag Antigen binding molecules having modified fc regions and altered binding to fc receptors
PL2254586T3 (pl) * 2008-02-22 2015-09-30 Agency For Science Tech And Research Astarstar Cząstki mezenchymalnych komórek macierzystych
KR101298012B1 (ko) 2011-02-08 2013-08-26 (주)차바이오앤디오스텍 암세포로의 표적지향을 위한 자연살해 세포를 포함하는 림프구의 제조방법 및 이를 포함하는 약학 조성물
CN105848662A (zh) 2013-11-01 2016-08-10 南克维斯特公司 杀肿瘤和抗微生物组合物和方法
WO2018236887A1 (en) 2017-06-20 2018-12-27 Nantkwest, Inc. Methods for treating merkel cell carcinoma (mcc) using nk-92 cells
WO2019028337A1 (en) 2017-08-04 2019-02-07 Nantkwest, Inc. TREATMENT AND INHIBITION OF LEUKEMIA USING NK-92 CELLS

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040018183A1 (en) * 1997-04-30 2004-01-29 Hans Klingemann Modified natural killer cell lines and methods of use
CN103154731A (zh) * 2010-07-28 2013-06-12 坎瓦克斯生物技术公司 新的超灵敏的基于细胞的传感器及其应用
WO2013025598A1 (en) * 2011-08-12 2013-02-21 The Children's Hospital Of Philadelphia Degranulation indicator and methods of use thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
LUANA LUGINI，ET AL: "Immune Surveillance Properties of Human NK Cell-Derived Exosomes", 《J IMMUNOL》 *
刘辉: "基因修饰的NK-92细胞对erbB2阳性乳腺癌细胞的特异性杀伤", 《中国博士学位论文全文数据库》 *
马杰综述: "自然杀伤细胞与肿瘤免疫治疗研究进展", 《国际妇产科学杂志》 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109804064A (zh) * 2016-09-29 2019-05-24 南克维斯特公司 具有降低的免疫原性的hla i类缺陷的nk-92细胞
CN108324735A (zh) * 2017-01-20 2018-07-27 李莉 用于疾病治疗的胞外体制剂及其应用
CN108324735B (zh) * 2017-01-20 2024-02-09 李莉 用于疾病治疗的胞外体制剂及其应用
CN111670246A (zh) * 2018-01-31 2020-09-15 南克维斯特公司 5%人白蛋白在洗涤和收获培养基中的用途
CN108815186A (zh) * 2018-06-14 2018-11-16 上海鸣大生物科技有限公司 一种治疗hpv持续感染引起疾病的药物及制备方法与应用
WO2019238120A1 (zh) * 2018-06-14 2019-12-19 上海鸣大生物科技有限公司 一种治疗hpv持续感染引起疾病的药物及制备方法与应用

Also Published As

Publication number Publication date
EP3062800B1 (en) 2020-04-08
JP6603216B2 (ja) 2019-11-06
US20240366674A1 (en) 2024-11-07
AU2014342477B2 (en) 2019-08-01
KR20210144920A (ko) 2021-11-30
US20190192568A1 (en) 2019-06-27
US10772912B2 (en) 2020-09-15
AU2014342477A1 (en) 2016-05-26
JP2020073478A (ja) 2020-05-14
KR20230085215A (ko) 2023-06-13
EP3701957B1 (en) 2022-12-28
EP3062800A4 (en) 2017-04-19
US11975027B2 (en) 2024-05-07
WO2015066054A1 (en) 2015-05-07
US11304977B2 (en) 2022-04-19
CA2927977A1 (en) 2015-05-07
KR20250099421A (ko) 2025-07-01
JP2016539105A (ja) 2016-12-15
KR20160068976A (ko) 2016-06-15
EP3062800A1 (en) 2016-09-07
US10517895B2 (en) 2019-12-31
US20160250256A1 (en) 2016-09-01
EP4134085A1 (en) 2023-02-15
KR20220147705A (ko) 2022-11-03
US10258649B2 (en) 2019-04-16
US20190192569A1 (en) 2019-06-27
US11213547B2 (en) 2022-01-04
US20190125801A1 (en) 2019-05-02
US20220160768A1 (en) 2022-05-26
US10646516B2 (en) 2020-05-12
CN120501764A (zh) 2025-08-19
KR102476640B1 (ko) 2022-12-09
US20250170181A1 (en) 2025-05-29
EP3701957A1 (en) 2020-09-02
JP6870053B2 (ja) 2021-05-12
US12064450B2 (en) 2024-08-20
US20220175838A1 (en) 2022-06-09
US20200038445A1 (en) 2020-02-06
KR102329796B1 (ko) 2021-11-23
US20190192570A1 (en) 2019-06-27
CA2927977C (en) 2024-03-05
ES2935906T3 (es) 2023-03-13

Similar Documents

Publication Publication Date Title
US11975027B2 (en) Tumoricidal and antimicrobial compositions and methods
EP2399595B1 (en) Immunopotentiating composition and process for producing same
Fang et al. Enhanced bacterial tumor delivery by modulating the EPR effect and therapeutic potential of Lactobacillus casei
CN105943559A (zh) 细菌核糖核酸细胞壁组合物及其制备和使用方法
HK1228299A1 (en) Tumoricidal compositions
HK1228299B (en) Tumoricidal compositions
Chan et al. Transfer Factors: Properties, Mechanism of Action and Its Clinical Applications

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Address after: California, USA

Applicant after: Immunobiology Co.

Address before: California, USA

Applicant before: NANTKWEST, Inc.

CB02 Change of applicant information
RJ01 Rejection of invention patent application after publication

Application publication date: 20160810

RJ01 Rejection of invention patent application after publication